Deloitte awards RSL Revolutionary Labs' Groundbreaking Dermaceuticals εὖSKIN

RSL Revolutionary Labs Ltd, a leading healthcare-focused company, has welcomed its inclusion on Deloitte's prestigious 'Technology Fast 50 program' list.

According to the company’s announcement, “This acknowledgment underscores RSL's unwavering commitment to innovation, technology advancement, and their exceptional dedication to improving oncology care and wound management through revolutionary dermaceuticals, εὖSKIN.”

Deloitte's Technology Fast 50 program annually identifies and celebrates the top 50 technology companies in Cyprus and the Middle East experiencing rapid growth and making significant contributions to their respective industries. RSL Revolutionary Labs' selection for this esteemed recognition further solidifies their position as a pioneering force in the field of healthcare and highlights their outstanding dedication to fostering innovation.

RSL Revolutionary Labs Ltd specialises in offering unique skincare formulations tailored specifically for oncology patients under their innovative brand, 'εὖSKIN'. These advanced formulas are the result of close collaboration with esteemed scientists, dermatologists, and oncology specialists. According to the company, each formulation undergoes rigorous validation through extensive research and development, preclinical studies, and clinical data to ensure the provision of the best possible solutions for patients' unique needs. RSL's ultimate goal is to improve the lives of those affected by cancer by providing effective and innovative skincare solutions.

Dr Marianna Prokopi Demetriades, Co-Founder of RSL Revolutionary Labs, emphasises the company's ongoing pursuit of innovation within the field of dermatooncology. "We are incredibly proud of this recognition, which validates our relentless commitment to advancing dermatological solutions and achieving our mission of enabling a better quality of life for all," Demetriades stated.

RSL Revolutionary Labs' inclusion in Deloitte's 'Technology Fast 50 program' list reinforces their position as a leading biotechnology company revolutionising oncology care and wound management through their groundbreaking dermaceuticals, the company's announcement noted, adding, that their unwavering dedication to innovation and improving patient outcomes demonstrates their commitment to making a significant and lasting impact on the lives of individuals affected by cancer.